GYRE THERAPEUTICS INC (GYRE)
Health Care · Antifibrotic biopharmaceuticals · NASDAQ
A China-based biopharmaceutical company generating revenue from approved antifibrotic treatments while advancing late-stage candidates for liver and other organ fibrosis in the U.S. market.
What GYRE THERAPEUTICS INC does
Gyre Therapeutics is a commercial-stage biopharmaceutical company focused on developing and commercializing small-molecule therapies for organ fibrosis and inflammatory diseases. The company operates through a majority-owned subsidiary in China (Gyre Pharmaceuticals) where it commercializes antifibrotic products including ETUARY® (pirfenidone) and Etorel® (nintedanib) for pulmonary fibrosis, and Contiva® (avatrombopag) for hematologic conditions. In the U.S., the company is advancing late-stage clinical candidates such as F351 (Hydronidone) for liver fibrosis, with plans to leverage its established China commercial base to support pipeline advancement.
Themes: Organ fibrosis / antifibrotic therapies, Pulmonary fibrosis, Liver fibrosis, Small-molecule therapeutics, China-focused commercial platform
Fundamentals
- Price$6.44 as of 2026-08-24 close
- Market cap$718M as of 2026-08-24
- 1-year return-21.3% 2025-08-22 close $8.18 → 2026-08-24 close $6.44
- P/En/a negative earnings
- Net margin-5.4% as of 2026-08-24
- Gross margin+95.1% as of 2026-08-24
- ROE-6.3% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)+16.3% as of 2026-08-24
- Revenue CAGR (3y)+4.5% SEC XBRL
- Beta1.33 as of 2026-08-24
- Last reported earnings2026-08-07 SEC EDGAR Form 8-K (Item 2.02)
Dividend: at least 1 years of non-decreasing per-share dividends (SEC XBRL) — we do not hold the year before it, so the real streak may be longer.
How GYRE compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross margintop 10% 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Dividend coverage
Not assessed — last reported dividend predates the accounts. The most recent fiscal year in which GYRE reported a dividend payment is FY2022, while its reported financial statements run through FY2025. Coverage is therefore not assessed for the latest year — an FY2022 ratio would not describe GYRE today.
Coverage is derived from reported SEC EDGAR XBRL figures, comparing dividends paid against net income and free cash flow for the SAME fiscal year. It is not shown here because the latest fiscal year with a reported dividend payment (FY2022) is older than the latest year of reported financial statements (FY2025), so any ratio would describe an out-of-date year. Informational only — not financial advice.
How GYRE THERAPEUTICS INC looks technically
GYRE THERAPEUTICS INC (GYRE) is trading 4.4% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 74 trading days ago — a "death cross", a bearish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 24 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 59, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 3 trading days ago. It is 26.6% below its highest point of the past year.
Trend
7
| Distance from the 200-day | it is trading 4.4% below its 200-day average, the long-term trend line — a long-term downtrend | -4.4% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $6.39 | $6.39 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $7.23 | $7.23 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 25 calendar days ago — the swings before that are what the structure reading is measured on | 25 sessions |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 74 trading days ago — a "death cross", a bearish long-term signal | 74 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 24 (a reading of 25+ marks a strong trend) | 23.9 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 59, neither overbought (above 70) nor oversold (below 30) | 59.5 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($6.10 to $7.29) — its "stochastic" reading is 68 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 68.1 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 13 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $9.42 | $9.42 |
|---|---|---|
| From the 52-week high | it is 26.6% below its 52-week high (its highest price of the past year) | -26.6% |
| Above the 52-week low | it is 27.0% above its 52-week low (its lowest price of the past year) | +27.0% |
| Below the 52-week high | it is 26.6% below its highest point of the past year | 26.6% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day low about 54 trading days ago | 54 sessions |
| All-time high | its highest closing price on record is $47990.25 (set on 2011-03-01) | $47990.25 |
| Given back of the 52-week move | over the past year its closes ranged ($5.56 to $8.87), and it has recovered roughly a third of its fall from last year’s high — 41% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $7.61 to $7.71. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 40.8% |
| From the all-time high | it is 100.0% below its all-time high | -100.0% |
| Nearest price level | it is trading 1.3% below a resistance level at $7.00 — a price it turned at four times since 2025-07-01, most recently on 2025-12-19. Since 2024-08-21 it has 3 such levels below the current price and 14 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +1.3% |
| All-time low | its lowest closing price on record is $2.85 (set on 2023-03-13) | $2.85 |
| Above the all-time low | it is 142.5% above its all-time low | +142.5% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 77% of it) | 77th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.3262 between its high and its low — about 4.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.3262 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $5.57 and $7.32 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $5.57 – $6.45 – $7.32 |
| Typical daily range (% of price) | its price moves about 4.7% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.7% |
| Stretch from the 200-day average | it is trading 1.0 daily range below its 200-day average price (4.4% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.0 daily range below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.20× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 7 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 7 sessions ago |
|---|---|---|
| Since a bearish engulfing | 1 session ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 1 session ago |
Price gaps
2
| Gap at the open | it opened on 2026-08-21 0.9% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.8% |
|---|---|---|
| Gap filled | a 2.7% gap down opened on 2026-07-17 has been "filled" 13 sessions ago — price traded back through the level the gap left behind, and it took 12 sessions to close | 13 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -3.36% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 11.7 percentage points (the stock gained 14.0% while the market gained 2.3%) | +11.7% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 8.7 percentage points (the stock gained 11.8% while the market gained 3.1%) | +8.7% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 27.6 percentage points (the stock lost 16.5% while the market gained 11.1%) | -27.6% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 29.0 percentage points (the stock lost 8.5% while the market gained 20.5%) | -29.0% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a fresh 20-day high, MACD momentum is positive, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 2.1% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thin, spanning 0.8% of the share price, which is taken to mean a barrier that gives way easily. | +2.1% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 3% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $7.10 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | -2.7% |
|---|---|---|
| Vs the average paid since it last reported | the price is 1% above the average price paid since it last reported on 2026-08-07 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $6.81 — a volume-weighted average of daily closes over 11 sessions, not a true tick-by-tick VWAP. | +1.5% |
Price levels it has turned at before
GYRE last closed at $6.91 on 2026-08-21. Since 2024-08-21 it has turned at 3 prices below its last close and 14 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $7.00 | Resistance | 1.3% above the last close | turned there four times · 2025-07-01 to 2025-12-19 |
| $6.76 | Support | 2.1% below the last close | turned there twice · 2026-01-02 to 2026-03-30 |
| $7.13 | Resistance | 3.1% above the last close | turned there three times · 2025-09-19 to 2025-11-07 |
| $6.61 | Support | 4.4% below the last close | turned there four times · 2025-08-01 to 2026-06-05 |
| $7.39 | Resistance | 6.9% above the last close | turned there six times · 2025-08-20 to 2026-07-06 |
| $6.14 | Support | 11.1% below the last close | turned there twice · 2025-04-01 to 2025-04-09 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · Broke out to a new 20-day high · lagging the market · Trading above the Ichimoku cloud · Near a resistance level (pressing into a price that has capped it before) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.00 mean, 1=Strong Buy…5=Strong Sell) — 3 analysts
- Mean price target$18.67 range $18.00 – $20.00; median $18.00
Analyst estimates, as of 2026-08-21. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Key risks (from latest filing)
["Clinical development risk: F351 (Hydronidone) advancement depends on successful clinical trials; failure to demonstrate efficacy or safety could delay or prevent commercialization in the U.S.","Regulatory and reimbursement risk: Product access and pricing in the PRC are subject to government controls and National Reimbursement Drug List inclusion, which could impact ETUARY® sales and market position.","Merger integration risk: The pending Cullgen merger creates execution risk and may distract from core operations; failure to successfully consummate or integrate the transaction could impact the company's growth strategy."]
What changed in the latest 10-Q
AI-assisted comparison of GYRE's 10-Q filed 2026-05-08 against the prior one filed 2025-11-07.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-08) references audited consolidated financial statements for year ended December 31, 2025, versus older filing (2025-11-07) which referenced December 31, 2024.
- Newer filing adds disclosure of Cullgen Inc. acquisition completed in May 2026 pursuant to Merger Agreement dated March 2, 2026, with details on merger structure and transaction costs.
- Newer filing states company intends to leverage Cullgen's capabilities in PRC for development and early-stage clinical trials of product candidates.
- Newer filing discloses company has been engaged in evaluation of pipeline and clinical development strategy in connection with Cullgen acquisition to optimize capital allocation.
- Newer filing adds that ETUARY pirfenidone trial for pneumoconiosis completed enrollment of 272 patients in 52-week Phase 3 trial in 2025.
- Newer filing states NMPA approved clinical trial application for radiation-induced lung injury in March 2025 and adaptive Phase 2/3 study was initiated in April 2026.
- Newer filing specifies Etorel indicated for IPF, SSc-ILD, and progressive pulmonary fibrosis (PPF), adding PPF to indications.
- Newer filing discloses Etorel was selected under National Centralized Drug Procurement on November 7, 2025, with direct procurement contracts signed and implementation commenced March 2026.
- Newer filing discloses Contiva approval was specifically for treatment of thrombocytopenia associated with chronic liver disease in adult patients undergoing elective diagnostic procedures or therapy.
- Newer filing adds that Contiva received NMPA approval in June 2024 and another approval event in January 2025.
- Removed:
- Older filing (2025-11-07) contained detailed description of company as 'commercial-stage biotechnology company with a proven track record of financial success' and explanation of fibrotic diseases and multiple pathways—this detailed overview language removed in newer filing.
- Older filing described pirfenidone mechanism of action (inhibits TGF-ß1, TNF-α) and global approvals context—removed in newer filing.
- Older filing stated Phase 2/3 clinical trial for RILI 'expected to initiate in the fourth quarter of 2025'—removed in newer filing (now stated as initiated April 2026).
- Older filing described Etorel as approved for SSc-ILD and progressive fibrosing interstitial lung disease (PF-ILD)—newer filing changed to progressive pulmonary fibrosis (PPF) and added IPF.
- Older filing contained detailed discussion of Etorel commercialization strategy including market access, physician education, and patient support programs—removed in newer filing.
- Older filing described Contiva approval for both CLD-associated TCP and ITP in March 2025—newer filing specifies June 2024 approval and separate January 2025 event, removing ITP reference.
- Older filing included section on Hydronidone as lead development candidate with Phase 3 trial completion details—this section is cut off in newer filing excerpt but appears substantially removed or relocated.
- Reworded:
- Older filing described company as 'commercial-stage biotechnology company'; newer filing (2026-05-08) describes as 'commercial-stage biopharmaceutical company'.
- Older filing strategy: 'build on our success in the development and commercialization of ETUARY® to expand into new indications'; newer filing: 'leverage our established commercial portfolio to support and de-risk the advancement of late-stage product candidates, expand approved products into additional indications'.
- Older filing reference to 'Part I — Item 1A' had spacing issue ('Part I —'); newer filing corrected to 'Part I - Item 1A'.
- Older filing: Etorel described as 'ethanesulfonate soft capsules'; newer filing: 'nintedanib esilate soft capsules'.
- Older filing: Etorel indications listed as 'SSc-ILD' and 'progressive fibrosing interstitial lung disease (PF-ILD)'; newer filing lists 'IPF, systemic sclerosis-associated interstitial lung disease (SSc-ILD), and progressive pulmonary fibrosis (PPF)'.
- Older filing: 'third quarter of 2025, this trial completed patient enrollment'; newer filing: 'in 2025, we completed enrollment of 272 patients in our 52-week Phase 3 trial'.
- Older filing: Contiva indication 'thrombocytopenia (TCP) in adults with chronic liver disease (CLD) and immune thrombocytopenic purpura (ITP)'; newer filing: 'thrombocytopenia associated with chronic liver disease in adult patients undergoing elective diagnostic procedures or therapy'.
- Notes:
- Newer filing text appears truncated at end of Contiva section ('In January 2025, the NMP'), making full comparison of that product description incomplete.
- Hydronidone section in older filing is cut off in the provided text, so complete removal or relocation cannot be fully assessed.
- Older filing's detailed mechanism of action and disease biology explanation cannot be fully compared as newer filing takes different structural approach.
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 8 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 8 sells ($433423) — 1 selling insider
- Last 180 days0 buys · 18 sells ($952875) — 2 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-06-18. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about GYRE's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
3 institutional 13F filers reported holding GYRE as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 3
- Reported shares held 993,673
- Reported value $6,925,899
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
GYRE had 1,823,720 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
GYRE had 1.64% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 37.39 days to cover at the same settlement.
- Reported short interest (shares) 1,823,720
- Short interest (% of shares outstanding) 1.64%
- Prior settlement (shares) 2,043,169
- Reported change -10.74%
- Days to cover (reported) 37.39
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Roche (RHHBY)
- Boehringer Ingelheim
- Shionogi
- FibroGen (FGEN)
- Galapagos (GLPG)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Frequently asked questions
What does GYRE THERAPEUTICS INC (GYRE) do?
Gyre Therapeutics is a commercial-stage biopharmaceutical company focused on developing and commercializing small-molecule therapies for organ fibrosis and inflammatory diseases. The company operates through a majority-owned subsidiary in China (Gyre Pharmaceuticals) where it commercializes antifibrotic products including ETUARY® (pirfenidone) and Etorel® (nintedanib) for pulmonary fibrosis, and Contiva® (avatrombopag) for hematologic conditions.
What sector is GYRE THERAPEUTICS INC (GYRE) in?
GYRE THERAPEUTICS INC (GYRE) is classified in the Health Care sector. Its industry is Antifibrotic biopharmaceuticals. It trades on NASDAQ.
Who are GYRE THERAPEUTICS INC's (GYRE) competitors?
Notable peers of GYRE THERAPEUTICS INC (GYRE) include Roche, Boehringer Ingelheim, Shionogi, FibroGen and Galapagos. This peer set is informational only — not financial advice.
Is GYRE THERAPEUTICS INC (GYRE) overbought or oversold right now?
GYRE THERAPEUTICS INC (GYRE) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 59, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on GYRE come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.